Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version

Changes to This Summary (11/09/2018)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Risk-Based Treatment Assignment

Added Swerdlow et al. as reference 93, Winter et al. as reference 100, and Borowitz et al. as reference 115.

Postinduction Treatment for Specific Acute Lymphoblastic Leukemia (ALL) Subgroups

Revised text to state that another example is the Children's Oncology Group (COG) trial for T-cell ALL (AALL0434) that resulted in a 5-year event-free survival rate of 83.8% and an overall survival rate of 89.5% (cited Winter et al. as reference 3).

Revised text about treatments and outcomes of patients with T-cell ALL who were enrolled in the COG AALL0434 trial.

Added text about the A041501 (NCT03150693) trial as a treatment option under clinical evaluation for adolescent and young adult patients with ALL.

Treatment of Relapsed Childhood ALL

Added text about the presentation and treatment of cytokine release syndrome.

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Treatment of Relapsed Childhood ALL

Next section >
About This PDQ Summary